Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2012

Open Access 01-12-2012 | Research

The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy

Authors: Liting Deng, Josée Guindon, V Kiran Vemuri, Ganesh A Thakur, Fletcher A White, Alexandros Makriyannis, Andrea G Hohmann

Published in: Molecular Pain | Issue 1/2012

Login to get access

Abstract

Background

Chemotherapeutic agents produce dose-limiting peripheral neuropathy through mechanisms that remain poorly understood. We previously showed that AM1710, a cannabilactone CB2 agonist, produces antinociception without producing central nervous system (CNS)-associated side effects. The present study was conducted to examine the antinociceptive effect of AM1710 in rodent models of neuropathic pain evoked by diverse chemotherapeutic agents (cisplatin and paclitaxel). A secondary objective was to investigate the potential contribution of alpha-chemokine receptor (CXCR4) signaling to both chemotherapy-induced neuropathy and CB2 agonist efficacy.

Results

AM1710 (0.1, 1 or 5 mg/kg i.p.) suppressed the maintenance of mechanical and cold allodynia in the cisplatin and paclitaxel models. Anti-allodynic effects of AM1710 were blocked by the CB2 antagonist AM630 (3 mg/kg i.p.), but not the CB1 antagonist AM251 (3 mg/kg i.p.), consistent with a CB2-mediated effect. By contrast, blockade of CXCR4 signaling with its receptor antagonist AMD3100 (10 mg/kg i.p.) failed to attenuate mechanical or cold hypersensitivity induced by either cisplatin or paclitaxel. Moreover, blockade of CXCR4 signaling failed to alter the anti-allodynic effects of AM1710 in the paclitaxel model, further suggesting distinct mechanisms of action.

Conclusions

Our results indicate that activation of cannabinoid CB2 receptors by AM1710 suppresses both mechanical and cold allodynia in two distinct models of chemotherapy-induced neuropathic pain. By contrast, CXCR4 signaling does not contribute to the maintenance of chemotherapy-induced established neuropathy or efficacy of AM1710. Our studies suggest that CB2 receptors represent a promising therapeutic target for the treatment of toxic neuropathies produced by cisplatin and paclitaxel chemotherapeutic agents.
Appendix
Available only for authorised users
Literature
1.
Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E: Chemotherapy-induced neuropathy. Curr Treat Options Neurol 2011, 13: 180–190. 10.1007/s11940-010-0108-3CrossRefPubMed
2.
Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C: Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44: 1507–1515. 10.1016/j.ejca.2008.04.018CrossRefPubMed
3.
Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993, 20: 1–15.PubMed
4.
Windebank AJ, Grisold W: Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13: 27–46. 10.1111/j.1529-8027.2008.00156.xCrossRefPubMed
5.
Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, Tredici G: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69: 203–207. 10.1002/1097-0142(19920101)69:1<203::AID-CNCR2820690133>3.0.CO;2-1CrossRefPubMed
6.
Uhm JH, Yung WK: Neurologic Complications of Cancer Therapy. Curr Treat Options Neurol 1999, 1: 428–437. 10.1007/s11940-996-0006-xCrossRefPubMed
7.
Polomano RC, Bennett GJ: Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2001, 2: 8–14. 10.1046/j.1526-4637.2001.002001008.xCrossRefPubMed
8.
Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A: Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009, 6: 620–629. 10.1016/j.nurt.2009.07.003CrossRefPubMed
9.
Pachman DR, Barton DL, Watson JC, Loprinzi CL: Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011, 90: 377–387. 10.1038/clpt.2011.115CrossRefPubMed
10.
Hohmann AG: A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy. Pain 2005, 118: 3–5. 10.1016/j.pain.2005.07.007CrossRefPubMed
11.
12.
Leung L: Cannabis and its derivatives: review of medical use. J Am Board Fam Med 2011, 24: 452–462. 10.3122/jabfm.2011.04.100280CrossRefPubMed
13.
Pertwee RG: Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009, 156: 397–411. 10.1111/j.1476-5381.2008.00048.xPubMedCentralCrossRefPubMed
14.
Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG: Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 2008, 327: 584–591. 10.1124/jpet.108.141994PubMedCentralCrossRefPubMed
15.
Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P, Brown DL: MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 2008, 155: 1104–1116.PubMedCentralCrossRefPubMed
16.
Naguib M, Xu JJ, Diaz P, Brown DL, Cogdell D, Bie B, Hu J, Craig S, Hittelman WN: Prevention of Paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg 2012, 114: 1104–1120. 10.1213/ANE.0b013e31824b0191PubMedCentralCrossRefPubMed
17.
Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M: Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg 2010, 111: 99–109.PubMedCentralPubMed
18.
Rahn EJ, Makriyannis A, Hohmann AG: Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007, 152: 765–777.PubMedCentralCrossRefPubMed
19.
Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG: Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav 2011, 98: 493–502. 10.1016/j.pbb.2011.02.024PubMedCentralCrossRefPubMed
20.
Khanolkar AD, Lu D, Ibrahim M, Duclos RI Jr, Thakur GA, Malan TP Jr, Porreca F, Veerappan V, Tian X, George C, et al.: Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem 2007, 50: 6493–6500. 10.1021/jm070441uCrossRefPubMed
21.
Jaggi AS, Singh N: Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012, 291: 1–9. 10.1016/j.tox.2011.10.019CrossRefPubMed
22.
Gao YJ, Ji RR: Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 2010, 126: 56–68. 10.1016/j.pharmthera.2010.01.002PubMedCentralCrossRefPubMed
23.
Dubovy P, Klusakova I, Svizenska I, Brazda V: Spatio-temporal changes of SDF1 and its CXCR4 receptor in the dorsal root ganglia following unilateral sciatic nerve injury as a model of neuropathic pain. Histochem Cell Biol 2010, 133: 323–337. 10.1007/s00418-010-0675-0CrossRefPubMed
24.
Bhangoo SK, Ren D, Miller RJ, Chan DM, Ripsch MS, Weiss C, McGinnis C, White FA: CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. Brain Behav Immun 2007, 21: 581–591. 10.1016/j.bbi.2006.12.003PubMedCentralCrossRefPubMed
25.
Bhangoo SK, Ripsch MS, Buchanan DJ, Miller RJ, White FA: Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol Pain 2009, 5: 48. 10.1186/1744-8069-5-48PubMedCentralCrossRefPubMed
26.
Rahn EJ, Thakur GA, Zvonok AM, Vemuri VK, Makriyannis A, Hohmann AG: Prophylactic treatment with cannabinoids suppresses the development of neuropathic nociception resulting from treatment with the chemotherapeutic agent paclitaxel in rats. Society for Neuroscience Abstract Viewer/Itinerary Planner CD-ROM 2010., 681.3:
27.
Jhaveri MD, Sagar DR, Elmes SJ, Kendall DA, Chapman V: Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007, 36: 26–35. 10.1007/s12035-007-8007-7CrossRefPubMed
28.
Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, et al.: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310: 329–332. 10.1126/science.1115740CrossRefPubMed
29.
Guindon J, Hohmann AG: Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008, 153: 319–334. 10.1038/sj.bjp.0707531PubMedCentralCrossRefPubMed
30.
Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, Birch R, Benham C, Bountra C, Chessell IP, Anand P: Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008, 138: 667–680. 10.1016/j.pain.2008.06.007CrossRefPubMed
31.
Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E: HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999, 96: 14228–14233. 10.1073/pnas.96.25.14228PubMedCentralCrossRefPubMed
32.
Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP Jr: Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003, 100: 10529–10533. 10.1073/pnas.1834309100PubMedCentralCrossRefPubMed
33.
Wilkerson JL, Gentry KR, Dengler EC, Wallace JA, Kerwin AA, Armijo LM, Kuhn MN, Thakur GA, Makriyannis A, Milligan ED: Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain 2012, 153: 1091–1106. 10.1016/j.pain.2012.02.015PubMedCentralCrossRefPubMed
34.
Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC: Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54: 1269–1275. 10.1002/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9CrossRefPubMed
35.
Roelofs RI, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984, 34: 934–938. 10.1212/WNL.34.7.934CrossRefPubMed
36.
Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik P, Schaumburg HH: Taxol produces a predominantly sensory neuropathy. Neurology 1989, 39: 368–373. 10.1212/WNL.39.3.368CrossRefPubMed
37.
Petrenko AB, Yamakura T, Baba H, Shimoji K: The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003, 97: 1108–1116.CrossRefPubMed
38.
Carozzi VA, Chiorazzi A, Canta A, Lapidus RG, Slusher BS, Wozniak KM, Cavaletti G: Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 2010, 17: 380–391. 10.1007/s12640-009-9114-1CrossRefPubMed
39.
Pascual D, Goicoechea C, Burgos E, Martin MI: Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats. Pharmacol Biochem Behav 2010, 95: 331–337. 10.1016/j.pbb.2010.02.009CrossRefPubMed
40.
Zhang H, Yoon SY, Dougherty PM: Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain 2012, 13: 293–303. 10.1016/j.jpain.2011.12.002PubMedCentralCrossRefPubMed
41.
Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ: Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010, 6: 15. 10.1186/1744-8069-6-15PubMedCentralCrossRefPubMed
42.
Alessandri-Haber N, Dina OA, Joseph EK, Reichling DB, Levine JD: Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. J Neurosci 2008, 28: 1046–1057. 10.1523/JNEUROSCI.4497-07.2008CrossRefPubMed
43.
Flatters SJ, Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006, 122: 245–257. 10.1016/j.pain.2006.01.037PubMedCentralCrossRefPubMed
44.
Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, Taroni F, Lauria G: Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 2008, 214: 276–284. 10.1016/j.expneurol.2008.08.013CrossRefPubMed
45.
Xiao WH, Zheng H, Zheng FY, Nuydens R, Meert TF, Bennett GJ: Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 2011, 199: 461–469.PubMedCentralCrossRefPubMed
46.
Zheng H, Xiao WH, Bennett GJ: Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011, 232: 154–161. 10.1016/j.expneurol.2011.08.016PubMedCentralCrossRefPubMed
47.
Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA, Seybold VS: Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012, 32: 7091–7101. 10.1523/JNEUROSCI.0403-12.2012PubMedCentralCrossRefPubMed
48.
Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG: Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 2004, 92: 3562–3574. 10.1152/jn.00886.2003CrossRefPubMed
49.
Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall DA, Chapman V: Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 2005, 22: 371–379. 10.1111/j.1460-9568.2005.04206.xCrossRefPubMed
50.
Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V: Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 2004, 20: 2311–2320. 10.1111/j.1460-9568.2004.03690.xCrossRefPubMed
51.
52.
Anand P, Whiteside G, Fowler CJ, Hohmann AG: Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 2009, 60: 255–266. 10.1016/j.brainresrev.2008.12.003PubMedCentralCrossRefPubMed
53.
Burgos E, Gomez-Nicola D, Pascual D, Martin MI, Nieto-Sampedro M, Goicoechea C: Cannabinoid agonist WIN 55,212–2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol 2012, 682: 62–72. 10.1016/j.ejphar.2012.02.008CrossRefPubMed
54.
Oh JW, Drabik K, Kutsch O, Choi C, Tousson A, Benveniste EN: CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 2001, 166: 2695–2704.CrossRefPubMed
55.
Kajander KC, Bennett GJ: Onset of a painful peripheral neuropathy in rat: a partial and differential deafferentation and spontaneous discharge in A beta and A delta primary afferent neurons. J Neurophysiol 1992, 68: 734–744.PubMed
56.
Wu G, Ringkamp M, Murinson BB, Pogatzki EM, Hartke TV, Weerahandi HM, Campbell JN, Griffin JW, Meyer RA: Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J Neurosci 2002, 22: 7746–7753.PubMed
57.
Tanner KD, Levine JD, Topp KS: Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 1998, 395: 481–492. 10.1002/(SICI)1096-9861(19980615)395:4<481::AID-CNE5>3.0.CO;2-YCrossRefPubMed
58.
Topp KS, Tanner KD, Levine JD: Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000, 424: 563–576. 10.1002/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-UCrossRefPubMed
59.
Tanner KD, Reichling DB, Levine JD: Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 1998, 18: 6480–6491.PubMed
60.
Siau C, Xiao W, Bennett GJ: Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006, 201: 507–514. 10.1016/j.expneurol.2006.05.007PubMedCentralCrossRefPubMed
61.
Xiao WH, Bennett GJ: Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 2008, 135: 262–270. 10.1016/j.pain.2007.06.001PubMedCentralCrossRefPubMed
62.
Dina OA, Chen X, Reichling D, Levine JD: Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001, 108: 507–515. 10.1016/S0306-4522(01)00425-0CrossRefPubMed
63.
Benamar K, Geller EB, Adler MW: First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain. J Pharmacol Exp Ther 2008, 325: 641–645. 10.1124/jpet.107.135053CrossRefPubMed
64.
Benamar K, Yondorf M, Geller EB, Eisenstein TK, Adler MW: Physiological evidence for interaction between the HIV-1 co-receptor CXCR4 and the cannabinoid system in the brain. Br J Pharmacol 2009, 157: 1225–1231. 10.1111/j.1476-5381.2009.00285.xPubMedCentralCrossRefPubMed
65.
Ghosh S, Preet A, Groopman JE, Ganju RK: Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 2006, 43: 2169–2179. 10.1016/j.molimm.2006.01.005CrossRefPubMed
66.
Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, Ganju RK: Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One 2011, 6: e23901. 10.1371/journal.pone.0023901PubMedCentralCrossRefPubMed
67.
Cao L, DeLeo JA: CNS-infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection-induced neuropathic pain. Eur J Immunol 2008, 38: 448–458. 10.1002/eji.200737485PubMedCentralCrossRefPubMed
68.
Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16: 109–110. 10.1016/0304-3959(83)90201-4CrossRefPubMed
69.
Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F: An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003, 182: 12–20. 10.1016/S0014-4886(03)00003-7CrossRefPubMed
70.
Polomano RC, Mannes AJ, Clark US, Bennett GJ: A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001, 94: 293–304. 10.1016/S0304-3959(01)00363-3CrossRefPubMed
71.
Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, et al.: Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007, 13: 35–37. 10.1038/nm1521CrossRefPubMed
72.
Guindon J, Desroches J, Dani M, Beaulieu P: Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. Eur J Pharmacol 2007, 568: 173–176. 10.1016/j.ejphar.2007.04.060CrossRefPubMed
73.
Wilson NM, Jung H, Ripsch MS, Miller RJ, White FA: CXCR4 signaling mediates morphine-induced tactile hyperalgesia. Brain Behav Immun 2011, 25: 565–573. 10.1016/j.bbi.2010.12.014PubMedCentralCrossRefPubMed
74.
Choi Y, Yoon YW, Na HS, Kim SH, Chung JM: Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994, 59: 369–376. 10.1016/0304-3959(94)90023-XCrossRefPubMed
Metadata
Title
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy
Authors
Liting Deng
Josée Guindon
V Kiran Vemuri
Ganesh A Thakur
Fletcher A White
Alexandros Makriyannis
Andrea G Hohmann
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2012
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-8-71

Other articles of this Issue 1/2012

Molecular Pain 1/2012 Go to the issue

Research

1,8-cineole, a TRPM8 agonist, is a novel natural antagonist of human TRPA1

Research

CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy

Research

In vivo USPIO magnetic resonance imaging shows that minocycline mitigates macrophage recruitment to a peripheral nerve injury

Research

Milnacipran inhibits glutamatergic N-Methyl-D-Aspartate receptor activity in Spinal Dorsal Horn Neurons

Research

Upregulation of cystathionine beta-synthetase expression by nuclear factor-kappa B activation contributes to visceral hypersensitivity in adult rats with neonatal maternal deprivation

Research

Sea-anemone toxin ATX-II elicits A-fiber-dependent pain and enhances resurgent and persistent sodium currents in large sensory neurons